278 related articles for article (PubMed ID: 19051134)
1. An update on pharmacogenomics in rheumatoid arthritis with a focus on TNF-blocking agents.
Ranganathan P
Curr Opin Mol Ther; 2008 Dec; 10(6):562-7. PubMed ID: 19051134
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomics of tumor necrosis factor antagonists in rheumatoid arthritis.
Ranganathan P
Pharmacogenomics; 2005 Jul; 6(5):481-90. PubMed ID: 16013998
[TBL] [Abstract][Full Text] [Related]
3. [Current aspects of cost effectiveness of TNF-alpha blocking agents in patients with rheumatoid arthritis].
Merkesdal S; Ruof J
Z Rheumatol; 2002; 61 Suppl 2():II/29-32. PubMed ID: 12491120
[TBL] [Abstract][Full Text] [Related]
4. Does polymorphysm of genes coding for pro-inflammatory mediators predict the clinical response to tnf alpha blocking agents? A review analysis of the literature.
Ingegnoli F; Favalli EG; Meroni PL
Autoimmun Rev; 2011 Jun; 10(8):460-3. PubMed ID: 21296193
[TBL] [Abstract][Full Text] [Related]
5. Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis.
Wu E; Chen L; Birnbaum H; Yang E; Cifaldi M
Curr Med Res Opin; 2008 Aug; 24(8):2229-40. PubMed ID: 18577308
[TBL] [Abstract][Full Text] [Related]
6. Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-alpha therapy.
Gonzalez-Gay MA; Gonzalez-Juanatey C; Vazquez-Rodriguez TR; Miranda-Filloy JA; Llorca J
Ann N Y Acad Sci; 2010 Apr; 1193():153-9. PubMed ID: 20398022
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of anti-TNF treatment in patients with rheumatoid arthritis.
Coenen MJ; Toonen EJ; Scheffer H; Radstake TR; Barrera P; Franke B
Pharmacogenomics; 2007 Jul; 8(7):761-73. PubMed ID: 17638513
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenomics in rheumatoid arthritis.
Ranganathan P
Methods Mol Biol; 2008; 448():413-35. PubMed ID: 18370240
[TBL] [Abstract][Full Text] [Related]
9. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
Cañete JD; Suárez B; Hernández MV; Sanmartí R; Rego I; Celis R; Moll C; Pinto JA; Blanco FJ; Lozano F
Ann Rheum Dis; 2009 Oct; 68(10):1547-52. PubMed ID: 18930989
[TBL] [Abstract][Full Text] [Related]
10. TNF inhibitors - new and old agents for rheumatoid arthritis.
Simsek I
Bull NYU Hosp Jt Dis; 2010; 68(3):204-10. PubMed ID: 20969553
[TBL] [Abstract][Full Text] [Related]
11. Genetic variants that predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis: current challenges and future directions.
Plenge RM; Criswell LA
Curr Opin Rheumatol; 2008 Mar; 20(2):145-52. PubMed ID: 18349743
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomics of infliximab treatment using peripheral blood cells of patients with rheumatoid arthritis.
van Baarsen LG; Wijbrandts CA; Gerlag DM; Rustenburg F; van der Pouw Kraan TC; Dijkmans BA; Tak PP; Verweij CL
Genes Immun; 2010 Dec; 11(8):622-9. PubMed ID: 20555356
[TBL] [Abstract][Full Text] [Related]
13. Personalized medicine in rheumatoid arthritis: hopes and challenges.
Bridges SL
Bull NYU Hosp Jt Dis; 2007; 65(3):174-7. PubMed ID: 17922665
[TBL] [Abstract][Full Text] [Related]
14. Changing patterns of tumor necrosis factor inhibitor use in 9074 patients with rheumatoid arthritis.
Yazici Y; Krasnokutsky S; Barnes JP; Hines PL; Wang J; Rosenblatt L
J Rheumatol; 2009 May; 36(5):907-13. PubMed ID: 19332636
[TBL] [Abstract][Full Text] [Related]
15. [Rituximab (Mabthera)--treatment of rheumatoid arthritis patients with inadequate response to TNF inhibitors--when to change therapy?].
Morović-Vergles J
Reumatizam; 2008; 55(2):70-2. PubMed ID: 19024280
[TBL] [Abstract][Full Text] [Related]
16. Stress activation of cellular markers of inflammation in rheumatoid arthritis: protective effects of tumor necrosis factor alpha antagonists.
Motivala SJ; Khanna D; FitzGerald J; Irwin MR
Arthritis Rheum; 2008 Feb; 58(2):376-83. PubMed ID: 18240230
[TBL] [Abstract][Full Text] [Related]
17. TNF inhibitors for rheumatoid arthritis - a year in review.
Simsek I
Bull NYU Hosp Jt Dis; 2011; 69(3):220-4. PubMed ID: 22035432
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacogenomics of methrotexate: a strategy for a customized therapeutic scheme for patients with rheumatoid arthritis].
Mena-Ramírez JP; Salazar-Páramo M; Dávalos-Rodríguez IP
Gac Med Mex; 2008; 144(5):449-51. PubMed ID: 19043967
[TBL] [Abstract][Full Text] [Related]
19. [Proposal for anti-TNFalpha therapy in adult patients with rheumatoid arthritis].
Curković B; Babić-Naglić D; Morović-Vergles J; Anić B; Grazio S
Reumatizam; 2007; 54(1):16-9. PubMed ID: 18450272
[TBL] [Abstract][Full Text] [Related]
20. Treatment of rheumatoid arthritis in the 21st century: targeting B-lymphocytes.
Brezinschek HP; Brickmann K; Yazdani-Biuki B; Dörner T; Graninger WB; Brezinschek RI
Wien Med Wochenschr; 2006 Jan; 156(1-2):61-7. PubMed ID: 16465615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
